Hyppigheden af større molekylært respons ved 24 måneder var 45% (35% for imatinib- resistente patienter og 74% for imatinib- intolerante patienter).
The rate of major molecular response at 24 months was 45% (35% for imatinib-resistant patients and 74% for imatinib-intolerant patients).